Gabapentin dosing for neuropathic pain: Evidence from randomized, placebo-controlled clinical trials

  • Backonja M
  • Glanzman R
  • 15

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Abstract

Background: Pain is one of the most common reasons for seeking medical attention, and neuropathic pain is among the most common types of pain. Despite its prevalence, neuropathic pain is often underrecognized and inadequately treated. Many cases are refractory to the medications traditionally used for pain, such as nonsteroidal anti-inflammatory drugs. Tricyclic antidepressants are considered first-line agents for neuropathic pain, but their use is limited by unwanted side effects and a risk of cardiovascular mortality. Objectives: The goals of this article were to review data on the efficacy and tolerability of gabapentin in the treatment of neuropathic pain in adults and to determine the optimal dosing schedule. Methods: Randomized controlled studies of gabapentin for neuropathic pain were identified through a search of PubMed and MEDLINE from 1966 to the present using the search terms gabapentin, randomized, placebo, and pain. Abstracts of identified articles were screened for study size (>100 patients per treatment arm) and use of appropriate efficacy measures. A separate review based on information provided by the manufacturer of gabapentin and clinical trial Web sites was conducted to ascertain whether there had been any other relevant industry-or government-sponsored trials. The manufacturer provided additional unpublished study data. Results: Data from 5 randomized, placebo-controlled trials were included in the review, 1 of which has not yet been published. Gabapentin was effective in the treatment of painful diabetic neuropathy, postherpetic neuralgia, and other neuropathic pain syndromes. It relieved symptoms of allodynia, burning pain, shooting pain, and hyperesthesia. Adverse effects were typically mild to moderate and usually subsided within ∼10 days from the initiation of treatment. Based on available data, it appears that treatment should be started at a dose of 900 mg/d (300 mg/d on day 1, 600 mg/d on day 2, and 900 mg/d on day 3). Additional titration to 1800 mg/d is recommended for greater efficacy. Doses up to 3600 mg/d may be needed in some patients. The effective dose should be individualized according to patient response and tolerability. Conclusion: At doses of 1800 to 3600 mg/d, gabapentin was effective and well tolerated in the treatment of adults with neuropathic pain. Copyright © 2003 Excerpta Medica, Inc.

Author-supplied keywords

  • United Kingdom
  • United States
  • acetylsalicylic acid
  • allodynia
  • amitriptyline
  • analgesia
  • analgesic agent
  • anticonvulsive agent
  • antivirus agent
  • asthenia
  • benzodiazepine derivative
  • capsaicin
  • carbamazepine
  • cardiovascular risk
  • central nervous system disease
  • cerebrovascular accident
  • clinical trial
  • comorbidity
  • constipation
  • depression
  • dextromethorphan
  • diabetes mellitus
  • diabetic neuropathy
  • dose response
  • drug bioavailability
  • drug clearance
  • drug contraindication
  • drug efficacy
  • drug elimination
  • drug eruption
  • drug mechanism
  • drug potentiation
  • drug safety
  • drug structure
  • drug tolerability
  • elderly care
  • gabapentin
  • gastrointestinal symptom
  • heart disease
  • heart infarction
  • human
  • hyperesthesia
  • ibuprofen
  • kidney failure
  • lamotrigine
  • liver failure
  • mexiletine
  • monotherapy
  • muscle relaxant agent
  • nausea
  • neuropathic pain
  • neuropathology
  • nonsteroid antiinflammatory agent
  • opiate
  • outcomes research
  • oxycodone
  • peripheral edema
  • phenytoin
  • placebo
  • postherpetic neuralgia
  • quality of life
  • questionnaire
  • radiculopathy
  • review
  • sedation
  • side effect
  • somnolence
  • spinal cord injury
  • steroid
  • structure activity relation
  • sulindac
  • sweating
  • tramadol
  • tricyclic antidepressant agent
  • vertigo
  • visual analog scale
  • xerostomia

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • M Backonja

  • R L Glanzman

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free